Enhancing Effect of PS-K on IL-2-induced Lymphocyte Activation: Possible Involvement of Antagonistic Action Against TGF-beta

Anticancer Research

Volumn 24, Issue 2 B, 2004, Pages 639-647

  Yamaguchi, Yoshiyuki ^a,b   Minami, Kazuhito ^a   Ohshita, Akiko ^a   Kawabuchi, Yoshiharu ^a   Noma, Kosuke ^a   Toge, Tetsuya ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

IL 2; IL 2R; Lymphocyte proliferation; PS K; TGF beta

Indexed keywords

FLUOROKINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; POLYSACCHARIDE; PROTEIN; PROTEIN BOUND CARBOHYDRATE; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; CELL STRAIN K 562; CONTROLLED STUDY; CYTOTOXICITY; DAUDI CELL; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KIDNEY CELL; LYMPHOCYTE ACTIVATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BINDING;

ADJUVANTS, IMMUNOLOGIC; CELL ADHESION; CELL DIFFERENTIATION; DRUG SYNERGISM; HUMANS; INTERLEUKIN-2; K562 CELLS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROTEOGLYCANS; RECEPTORS, INTERLEUKIN-2; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; TELOMERASE; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 2442621464     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ooi VE and Liu F: Immunomodulation and anti-cancer activity of polysaccharide-protein complexes. Curr Med Chem 7: 715-729, 2000.
2. Fisher M and Yang LX: Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res 22: 1737-1754, 2002.
3. Yefenof E, Gafanovitch I, Oron E, Bar M and Klein E: Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Cancer Immunol Immunother 41: 389-396, 1995.
4. Algarra I, Collado A, Garcia Lora A and Garrido F: Differential effect of protein-bound polysaccharide (PSK) on survival of experimental murine tumors. J Exp Clin Cancer Res 18: 39-46, 1999.
5. Fukushima M: Adjuvant therapy of gastric cancer: The Japanese experiences. Semin Oncol 23: 369-378, 1996.
6. Nakazato H, Koike A, Saji S, Ogawa N and Sakamoto J: Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet 343: 1122-1126, 1994.
7. Toge T and Yamaguchi Y: Protein-bound polysaccharide increases survival in resected gastric cancer cases stratified with a preoperative granulocyte and lymphocyte count. Oncol Rep 7: 1157-1161, 2000.
8. Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, Nishiyama K, Amano T, Takahashi T, Murayama N and Oka H: Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum 35: 123-130, 1992.
9. Yunoki S, Tanaka N, Hizuta A and Orita K: Enhancement of antitumor cytotoxicity of hepatic lymphocytes by oral administration of PSK. Int J Immunopharmacol 16: 123-130, 1994.
10. Okuzawa M, Shinohara H, Kobayashi T, Iwamoto M, Toyoda M and Tanigawa N: PSK, a protein-bound polysaccharide, overcomes defective maturation of dendritic cells exposed to tumor-derived factors in vitro. Int J Oncol 20: 1189-1195, 2002.
11. Iguchi C, Nio Y, Takeda H, Yamasawa K, Hirahara N, Toga T, Itakura M and Tamura K: Plant polysaccharide PSK: cytostatic effects on growth and invasion; modulating effect on the expression of HLA and adhesion molecules on human gastric and colonic tumor cell surface. Anticancer Res 21: 1007-1013, 2001.
12. Matsunaga K, Morita I, Oguchi Y, Fujii T, Yoshikumi C and Nomoto K: Restoration of immune responsiveness by a biological response modifier, PSK, in aged mice bearing syngeneic transplantable tumor. J Clin Lab Immunol 24: 143-149, 1987.
13. Saji S, Sakamoto J, Teramukai S, Kunieda K, Sugiyama Y, Ohashi Y and Nakazato H: Impact of splenectomy and immunochemotherapy on survival following gastrectomy for carcinoma: covariate interaction with immunosuppressive acidic protein, a serum marker for the host immune system. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer. Surg Today 29: 504-510, 1999.
14. Mule JJ, Schwarz SL, Roberts AB, Sporn MB and Rosenberg SA: Transforming growth factor-beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 26: 95-100, 1988.
15. Chen W and Wahl SM: TGF-beta: receptors, signaling pathways and autoimmunity. Curr Dir Autoimmun 5: 62-91, 2002.
16. Kasid A, Bell GI and Director EP: Effects of transforming growth factor-beta on human lymphokine-activated killer cell precursors. Autocrine inhibition of cellular proliferation and differentiation to immune killer cells. J Immunol 141: 690-698, 1988.
17. Ruegemer JJ, Ho SN, Augustine JA, Schlager JW, Bell MP, McKean DJ and Abraham RT: Regulatory effects of transforming growth factor-beta on IL-2- and IL-4-dependent T cell-cycle progression. J Immunol 144: 1767-1776, 1990.
18. Frolik CA, Dart LL, Meyers CA, Smith DM and Sporn MB: Purification and initial characterization of a type beta transforming growth factor from human placenta. Proc Natl Acad Sci USA 80: 3676-380, 1983.
19. Nilsen-Hamilton M: Transforming growth factor-beta and its actions on cellular growth and differentiation. Curr Top Dev Biol 24: 95-136, 1990.
20. Grotendorst GR, Smale G and Pencev D: Production of transforming growth factor beta by human peripheral blood monocytes and neutrophils. J Cellular Physiol 140: 396-402, 1989.
21. Minami K, Yamaguchi Y, Yoshida K, Quan CP and Toge T: Dysregulation of telomerase activity and expression in lymphokine-activated killer cells from advanced cancer patients: possible involvement in cancer-associated immunosuppression mechanism. Oncol Rep 8: 649-653, 2001.
22. Kariya Y, Inoue N, Kihara T and Fujii M: Activation of human natural killer cells by the protein bound polysaccharide PSK independently of interferon and interleukin-2. Immunology Lett 31: 241-245, 1992.
23. Nio Y, Shiraishi T, Tsubono M, Morimoto H, Tseng CC, Imai S and Tobe T: In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer. Cancer Immunol Immunother 32: 335-341, 1991.
24. Rosenstein M, Ettinghausen SE and Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137: 1735-1742, 1986.
25. Ballmer-Weber BK, Dummer R, Kung E, Burg G and Ballmer PE: Interleukin 2-induced increase of vascular permeability without decrease of the intravascular albumin pool. Br J Cancer 71: 78-82, 1995.
26. Harada M, Matsunaga K, Oguchi Y, Iijima H, Tamada K, Abe K, Takenoyama M, Ito O, Kimura G and Nomoto K: Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice. Int J Cancer 70: 362-372, 1997.
27. Habelhah H, Okada F, Nakai K, Choi SK, Hamada J, Kobayashi M and Hosokawa M: Polysaccharide K induces Mn superoxide dismutase (Mn-SOD) in tumor tissues and inhibits malignant progression of QR-32 tumor cells: possible roles of interferon alpha, tumor necrosis factor alpha and transforming growth factor beta in Mn-SOD induction by polysaccharide K. Cancer Immunol Immunother 46: 338-344, 1998.
28. Zhang H, Morisaki T, Matsunaga H, Sato N, Uchiyama A, Hashizume K, Nagumo F, Tadano J and Katano M: Protein-bound polysaccharide PSK inhibits tumor invasiveness by downregulation of TGF-betal and MMPs. Clin Exp Metastasis 18: 343-352, 2000.
29. Matsunaga K, Hosokawa A, Oohara M, Sugita N, Harada M and Nomoto K: Direct action of a protein-bound polysaccharide, PSK, on transforming growth factor-beta. Immunopharmacology 40: 219-230, 1998.
30. Toge T, Yamaguchi Y, Kegoya Y, Baba N, Yanagawa E and Hattori T: Blocking of lymphocyte surface binding sites for the soluble suppressor factor by protein-bound polysaccharide, PSK. Int J Immunopharmacol 11: 9-12, 1989.
31. Greene WC and Waldmann TA: Inhibition of human lymphocyte proliferation by the nonmitogenic lectin wheat germ agglutinin. J Immunol 124: 2979-2987, 1980.
32. Massague J: Subunit structure of a high-affinity receptor for type b-transforming growth factor. J Biol Chemistry 260: 7059-7066, 1985.
33. O'Grady P, Kuo MD, Baldassare JJ, Huang SS and Huang JS: Purification of a new type high molecular weight receptor (type V receptor) of transforming growth factor beta (TGF-beta) from bovine liver. Identification of the type V TGF-beta receptor in cultured cells. J Biol Chem 266: 8583-8589, 1991.